25 XP   0   0   10

Sonoma Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Sonoma Pharmaceuticals Inc together

PenkeI guess you are interested in Sonoma Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sonoma Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sonoma Pharmaceuticals Inc

I send you an email if I find something interesting about Sonoma Pharmaceuticals Inc.

Quick analysis of Sonoma Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Sonoma Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.43
Expected worth in 1 year
$0.50
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.07
Return On Investment
43.2%

For what price can you sell your share?

Current Price per Share
$0.17
Expected price per share
$0.1159 - $0.2439
How sure are you?
50%

1. Valuation of Sonoma Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.17

Intrinsic Value Per Share

$-9.01 - $-2.79

Total Value Per Share

$-8.58 - $-2.36

2. Growth of Sonoma Pharmaceuticals Inc (5 min.)




Is Sonoma Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$6.6m$7.4m-$597k-8.7%

How much money is Sonoma Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.2m-$2.2m$942k74.2%
Net Profit Margin-41.7%-88.2%--

How much money comes from the company's main activities?

3. Financial Health of Sonoma Pharmaceuticals Inc (5 min.)




What can you expect buying and holding a share of Sonoma Pharmaceuticals Inc? (5 min.)

Welcome investor! Sonoma Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Sonoma Pharmaceuticals Inc.

What can you expect buying and holding a share of Sonoma Pharmaceuticals Inc?

First you should know what it really means to hold a share of Sonoma Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Sonoma Pharmaceuticals Inc is $0.1681. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sonoma Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sonoma Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.43. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sonoma Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.06-33.0%-0.08-48.4%-0.11-64.7%-0.08-46.0%-0.08-46.4%
Usd Book Value Change Per Share0.0738.8%0.0210.8%-0.09-53.5%-0.02-12.7%0.013.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.0738.8%0.0210.8%-0.09-53.5%-0.02-12.7%0.013.1%
Usd Price Per Share0.18-0.75-2.55-4.24-3.68-
Price to Earnings Ratio-0.81--2.17--7.15-1.51--5.48-
Price-to-Total Gains Ratio2.77--5.33--19.04--31.56--51.02-
Price to Book Ratio0.42-1.69-5.08-7.70-5.77-
Price-to-Total Gains Ratio2.77--5.33--19.04--31.56--51.02-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1681
Number of shares5948
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.02
Usd Total Gains Per Share0.02-0.02
Gains per Quarter (5948 shares)107.95-126.68
Gains per Year (5948 shares)431.79-506.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104324220-507-517
208648540-1013-1024
30129512860-1520-1531
40172717180-2027-2038
50215921500-2534-2545
60259125820-3040-3052
70302330140-3547-3559
80345434460-4054-4066
90388638780-4560-4573
100431843100-5067-5080

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%5.035.00.012.5%6.066.00.08.3%
Book Value Change Per Share2.02.00.050.0%3.07.02.025.0%6.010.04.030.0%13.023.04.032.5%25.042.05.034.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.072.00.0%
Total Gains per Share2.02.00.050.0%3.07.02.025.0%6.010.04.030.0%13.023.04.032.5%25.042.05.034.7%

Fundamentals of Sonoma Pharmaceuticals Inc

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Fundamental data was last updated by Penke on 2024-04-12 18:44:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sonoma Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sonoma Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -27.6% means that $-0.28 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is -27.6%. The company is making a huge loss. -2
  • The TTM is -41.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-27.6%TTM-41.7%+14.1%
TTM-41.7%YOY-88.2%+46.5%
TTM-41.7%5Y-58.0%+16.3%
5Y-58.0%10Y-41.2%-16.8%
1.1.2. Return on Assets

Shows how efficient Sonoma Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -5.9% Return on Assets means that Sonoma Pharmaceuticals Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is -5.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.9%TTM-8.4%+2.5%
TTM-8.4%YOY-13.0%+4.5%
TTM-8.4%5Y-11.0%+2.6%
5Y-11.0%10Y-11.1%+0.1%
1.1.3. Return on Equity

Shows how efficient Sonoma Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -12.9% Return on Equity means Sonoma Pharmaceuticals Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is -12.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-18.8%+5.8%
TTM-18.8%YOY-29.3%+10.5%
TTM-18.8%5Y-22.8%+4.1%
5Y-22.8%10Y-18.9%-3.9%

1.2. Operating Efficiency of Sonoma Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sonoma Pharmaceuticals Inc is operating .

  • Measures how much profit Sonoma Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -26.9% means the company generated $-0.27  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is -26.9%. The company is operating very inefficient. -2
  • The TTM is -36.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-26.9%TTM-36.3%+9.4%
TTM-36.3%YOY-87.6%+51.3%
TTM-36.3%5Y-55.5%+19.1%
5Y-55.5%10Y-62.4%+6.9%
1.2.2. Operating Ratio

Measures how efficient Sonoma Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.27 means that the operating costs are $1.27 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is 1.269. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.363. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.269TTM1.363-0.094
TTM1.363YOY2.116-0.753
TTM1.3635Y1.655-0.291
5Y1.65510Y1.667-0.013

1.3. Liquidity of Sonoma Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sonoma Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.07 means the company has $4.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is 4.067. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.674. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.067TTM3.674+0.393
TTM3.674YOY3.004+0.670
TTM3.6745Y3.401+0.273
5Y3.40110Y3.698-0.297
1.3.2. Quick Ratio

Measures if Sonoma Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.72 means the company can pay off $1.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is 1.718. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.825. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.718TTM1.825-0.106
TTM1.825YOY1.363+0.462
TTM1.8255Y1.911-0.086
5Y1.91110Y2.496-0.585

1.4. Solvency of Sonoma Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sonoma Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sonoma Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.54 means that Sonoma Pharmaceuticals Inc assets are financed with 54.2% credit (debt) and the remaining percentage (100% - 54.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is 0.542. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.545. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.542TTM0.545-0.003
TTM0.545YOY0.552-0.007
TTM0.5455Y0.462+0.083
5Y0.46210Y0.356+0.106
1.4.2. Debt to Equity Ratio

Measures if Sonoma Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 118.4% means that company has $1.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sonoma Pharmaceuticals Inc:

  • The MRQ is 1.184. The company is able to pay all its debts with equity. +1
  • The TTM is 1.204. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.184TTM1.204-0.020
TTM1.204YOY1.243-0.038
TTM1.2045Y0.952+0.253
5Y0.95210Y0.648+0.304

2. Market Valuation of Sonoma Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sonoma Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Sonoma Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.81 means the investor is paying $-0.81 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sonoma Pharmaceuticals Inc:

  • The EOD is -0.757. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.813. Based on the earnings, the company is expensive. -2
  • The TTM is -2.175. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.757MRQ-0.813+0.055
MRQ-0.813TTM-2.175+1.362
TTM-2.175YOY-7.146+4.972
TTM-2.1755Y1.513-3.688
5Y1.51310Y-5.476+6.990
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sonoma Pharmaceuticals Inc:

  • The EOD is -0.594. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.637. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.631. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.594MRQ-0.637+0.043
MRQ-0.637TTM-5.631+4.994
TTM-5.631YOY-8.642+3.012
TTM-5.6315Y-13.623+7.992
5Y-13.62310Y-9.585-4.038
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sonoma Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Sonoma Pharmaceuticals Inc:

  • The EOD is 0.392. Based on the equity, the company is cheap. +2
  • The MRQ is 0.421. Based on the equity, the company is cheap. +2
  • The TTM is 1.690. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.392MRQ0.421-0.029
MRQ0.421TTM1.690-1.269
TTM1.690YOY5.079-3.389
TTM1.6905Y7.705-6.015
5Y7.70510Y5.771+1.934
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sonoma Pharmaceuticals Inc.

3.1. Institutions holding Sonoma Pharmaceuticals Inc

Institutions are holding 1.946% of the shares of Sonoma Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Geode Capital Management, LLC0.229203578000
2023-12-31JPMorgan Chase & Co0.2118033049330490
2023-12-31Millennium Management LLC0.2044031897318970
2023-12-31HRT FINANCIAL LLC0.1785027862278620
2023-12-31State Street Corporation0.155802431500
2023-12-31Goldman Sachs Group Inc0.1296020222202220
2023-12-31Tower Research Capital LLC0.06109518-15-0.1573
2023-12-31UBS Group AG0.05730893689360
2023-12-31Advisory Services Network, LLC0.01580246324630
2023-12-31BlackRock Inc0.014502266-609-21.1826
2023-12-31U.S. Bancorp0.0032050000
2023-12-31Wells Fargo & Co0.0007010567176.3158
2023-12-31Morgan Stanley - Brokerage Accounts0.000608600
2023-12-31Hanson Mcclain Inc0.000406500
2023-12-31Bank of America Corp0.000304400
2023-12-31Hbc Financial Services, PLLC00200
2023-09-30NewSquare Capital, LLC000-10-100
2023-12-31Renaissance Technologies Corp000-14006-100
2023-09-30Gradient Investments000-31-100
2023-09-30Virtu Financial LLC000-14732-100
Total 1.26310197110+95093+48.2%

3.2. Funds holding Sonoma Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Extended Market Index0.186302908300
2024-02-29Fidelity Nasdaq Composite Index0.03190497500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.02450381800
2023-12-31Northern Trust Extended Eq Market Idx0.01230192400
2023-12-31NT Ext Equity Mkt Idx Fd - L0.01230192400
2024-02-29Fidelity Series Total Market Index0.0110172200
2023-12-31Northern Trust Wilshire 50000.0023035500
2023-12-31NT US Market Cap Idx Fd - L0.0023035500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0017026000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0013020900
2023-12-31SSgA U.S. Extended Market Index Class I0.000203200
2024-03-31State St US Extended Mkt Indx NL Cl C0.000203200
2023-12-31SSgA U.S. Total Market Index Strategy0.00010900
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00010800
Total 0.286504470600.0%

3.3. Insider Transactions

Insiders are holding 1.557% of the shares of Sonoma Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2018-03-12Robert E MillerBUY24003.9720088
2018-03-09Robert E MillerBUY12003.920088
2018-03-08James J SchutzBUY24733.9935858
2017-11-29James J SchutzBUY4005.0315829
2017-11-29Robert E MillerBUY17905.0220088
2017-11-24James J SchutzBUY2545.0515429
2017-11-21Robert E MillerBUY20005.0320088
2017-08-10James J SchutzBUY9295.4615175
2017-08-10Marc UmscheidBUY6005.313392
2017-08-10Robert E MillerBUY22645.320088
2017-03-09Robert E MillerBUY7507.0215964
2017-03-08Robert E MillerBUY10006.9315964
2017-03-06Marc UmscheidBUY7506.82750
2017-03-03James J SchutzBUY8006.7811736
2016-12-08James J SchutzBUY10004.8811040
2016-12-08Robert E MillerBUY50004.8615964
2016-08-15James J SchutzBUY13283.666505
2016-02-25James J SchutzBUY5000125885
2014-11-17James J SchutzBUY62851.78
2013-08-16James SchutzBUY51002.3514600

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sonoma Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0650.018+259%-0.090+238%-0.021+133%0.005+1135%
Book Value Per Share--0.4290.442-3%0.480-11%0.560-23%0.695-38%
Current Ratio--4.0673.674+11%3.004+35%3.401+20%3.698+10%
Debt To Asset Ratio--0.5420.5450%0.552-2%0.462+17%0.356+52%
Debt To Equity Ratio--1.1841.204-2%1.243-5%0.952+24%0.648+83%
Dividend Per Share----0%-0%-0%-0%
Eps---0.055-0.081+47%-0.109+96%-0.077+39%-0.078+40%
Free Cash Flow Per Share---0.071-0.083+18%-0.082+16%-0.094+33%-0.124+75%
Free Cash Flow To Equity Per Share--0.014-0.012+191%-0.083+710%-0.034+347%-0.050+467%
Gross Profit Margin--1.0001.030-3%1.0000%1.006-1%1.0030%
Intrinsic Value_10Y_max---2.785--------
Intrinsic Value_10Y_min---9.013--------
Intrinsic Value_1Y_max---0.314--------
Intrinsic Value_1Y_min---0.567--------
Intrinsic Value_3Y_max---0.917--------
Intrinsic Value_3Y_min---2.006--------
Intrinsic Value_5Y_max---1.488--------
Intrinsic Value_5Y_min---3.763--------
Market Cap2623603.940-7%2815574.96011700087.410-76%39720833.000-93%66113258.548-96%57436090.407-95%
Net Profit Margin---0.276-0.417+51%-0.882+219%-0.580+110%-0.412+49%
Operating Margin---0.269-0.363+35%-0.876+226%-0.555+106%-0.624+132%
Operating Ratio--1.2691.363-7%2.116-40%1.655-23%1.667-24%
Pb Ratio0.392-7%0.4211.690-75%5.079-92%7.705-95%5.771-93%
Pe Ratio-0.757+7%-0.813-2.175+168%-7.146+779%1.513-154%-5.476+574%
Price Per Share0.168-7%0.1800.750-76%2.545-93%4.236-96%3.680-95%
Price To Free Cash Flow Ratio-0.594+7%-0.637-5.631+784%-8.642+1257%-13.623+2039%-9.585+1405%
Price To Total Gains Ratio2.580-7%2.769-5.335+293%-19.036+788%-31.558+1240%-51.022+1943%
Quick Ratio--1.7181.825-6%1.363+26%1.911-10%2.496-31%
Return On Assets---0.059-0.084+43%-0.130+119%-0.110+86%-0.111+88%
Return On Equity---0.129-0.188+45%-0.293+126%-0.228+76%-0.189+46%
Total Gains Per Share--0.0650.018+259%-0.090+238%-0.021+133%0.005+1135%
Usd Book Value--6692000.0006896500.000-3%7493500.000-11%8733050.000-23%10842700.000-38%
Usd Book Value Change Per Share--0.0650.018+259%-0.090+238%-0.021+133%0.005+1135%
Usd Book Value Per Share--0.4290.442-3%0.480-11%0.560-23%0.695-38%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.055-0.081+47%-0.109+96%-0.077+39%-0.078+40%
Usd Free Cash Flow---1105000.000-1300250.000+18%-1287000.000+16%-1473150.000+33%-1928850.000+75%
Usd Free Cash Flow Per Share---0.071-0.083+18%-0.082+16%-0.094+33%-0.124+75%
Usd Free Cash Flow To Equity Per Share--0.014-0.012+191%-0.083+710%-0.034+347%-0.050+467%
Usd Market Cap2623603.940-7%2815574.96011700087.410-76%39720833.000-93%66113258.548-96%57436090.407-95%
Usd Price Per Share0.168-7%0.1800.750-76%2.545-93%4.236-96%3.680-95%
Usd Profit---866000.000-1269000.000+47%-2211000.000+155%-1714650.000+98%-1470775.000+70%
Usd Revenue--3138000.0003077500.000+2%2717750.000+15%3620700.000-13%3770525.000-17%
Usd Total Gains Per Share--0.0650.018+259%-0.090+238%-0.021+133%0.005+1135%
 EOD+2 -6MRQTTM+24 -10YOY+25 -85Y+22 -1210Y+21 -13

4.2. Fundamental Score

Let's check the fundamental score of Sonoma Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.757
Price to Book Ratio (EOD)Between0-10.392
Net Profit Margin (MRQ)Greater than0-0.276
Operating Margin (MRQ)Greater than0-0.269
Quick Ratio (MRQ)Greater than11.718
Current Ratio (MRQ)Greater than14.067
Debt to Asset Ratio (MRQ)Less than10.542
Debt to Equity Ratio (MRQ)Less than11.184
Return on Equity (MRQ)Greater than0.15-0.129
Return on Assets (MRQ)Greater than0.05-0.059
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Sonoma Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.800
Ma 20Greater thanMa 500.156
Ma 50Greater thanMa 1000.153
Ma 100Greater thanMa 2000.165
OpenGreater thanClose0.170
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets14,618
Total Liabilities7,926
Total Stockholder Equity6,692
 As reported
Total Liabilities 7,926
Total Stockholder Equity+ 6,692
Total Assets = 14,618

Assets

Total Assets14,618
Total Current Assets12,502
Long-term Assets2,116
Total Current Assets
Cash And Cash Equivalents 2,406
Net Receivables 2,876
Inventory 2,955
Other Current Assets 4,009
Total Current Assets  (as reported)12,502
Total Current Assets  (calculated)12,246
+/- 256
Long-term Assets
Property Plant Equipment 738
Long-term Assets Other 456
Long-term Assets  (as reported)2,116
Long-term Assets  (calculated)1,194
+/- 922

Liabilities & Shareholders' Equity

Total Current Liabilities3,074
Long-term Liabilities4,852
Total Stockholder Equity6,692
Total Current Liabilities
Short-term Debt 225
Short Long Term Debt 44
Accounts payable 864
Other Current Liabilities 1,847
Total Current Liabilities  (as reported)3,074
Total Current Liabilities  (calculated)2,980
+/- 94
Long-term Liabilities
Capital Lease Obligations 341
Long-term Liabilities  (as reported)4,852
Long-term Liabilities  (calculated)341
+/- 4,511
Total Stockholder Equity
Common Stock2
Retained Earnings -193,282
Accumulated Other Comprehensive Income -2,823
Other Stockholders Equity 202,795
Total Stockholder Equity (as reported)6,692
Total Stockholder Equity (calculated)6,692
+/-0
Other
Capital Stock2
Cash and Short Term Investments 2,406
Common Stock Shares Outstanding 10,909
Current Deferred Revenue138
Liabilities and Stockholders Equity 14,618
Net Debt -2,021
Net Invested Capital 6,736
Net Working Capital 9,428
Property Plant and Equipment Gross 738
Short Long Term Debt Total 385



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-30
> Total Assets 
0
0
0
6,940
0
0
0
12,689
0
10,056
9,800
26,950
20,537
20,040
14,893
23,612
16,165
9,777
5,837
5,447
5,876
9,970
8,576
10,218
10,374
9,303
8,413
8,664
9,210
7,763
8,981
7,838
9,693
13,392
11,830
12,565
10,581
8,882
9,843
20,791
19,879
18,394
11,834
15,048
14,206
13,584
12,098
13,803
11,320
9,241
27,507
25,459
22,421
20,153
18,355
19,206
16,633
14,348
17,045
14,448
14,448
16,145
16,496
14,561
14,561
18,145
18,231
14,987
14,987
19,828
19,347
18,845
18,845
14,962
13,928
16,231
15,893
13,635
14,618
14,61813,63515,89316,23113,92814,96218,84518,84519,34719,82814,98714,98718,23118,14514,56114,56116,49616,14514,44814,44817,04514,34816,63319,20618,35520,15322,42125,45927,5079,24111,32013,80312,09813,58414,20615,04811,83418,39419,87920,7919,8438,88210,58112,56511,83013,3929,6937,8388,9817,7639,2108,6648,4139,30310,37410,2188,5769,9705,8765,4475,8379,77716,16523,61214,89320,04020,53726,9509,80010,056012,6890006,940000
   > Total Current Assets 
0
0
0
4,881
0
0
0
10,227
0
5,433
5,105
23,868
17,572
17,242
12,207
20,950
13,620
7,756
4,077
3,942
4,368
8,590
7,249
9,050
9,290
8,233
7,405
7,809
8,357
6,922
8,172
6,960
8,869
12,447
10,900
11,534
8,951
6,912
7,493
9,542
8,668
7,291
5,197
9,647
13,264
12,677
11,139
12,888
10,497
8,392
25,127
22,643
19,313
17,199
15,672
16,254
13,993
11,668
14,579
12,496
12,496
13,310
13,858
12,383
12,383
16,267
16,212
12,983
12,983
18,021
17,699
16,430
16,430
12,393
11,232
13,798
13,587
11,516
12,502
12,50211,51613,58713,79811,23212,39316,43016,43017,69918,02112,98312,98316,21216,26712,38312,38313,85813,31012,49612,49614,57911,66813,99316,25415,67217,19919,31322,64325,1278,39210,49712,88811,13912,67713,2649,6475,1977,2918,6689,5427,4936,9128,95111,53410,90012,4478,8696,9608,1726,9228,3577,8097,4058,2339,2909,0507,2498,5904,3683,9424,0777,75613,62020,95012,20717,24217,57223,8685,1055,433010,2270004,881000
       Cash And Cash Equivalents 
0
0
0
3,287
0
0
0
7,448
0
2,269
2,520
19,050
12,850
14,948
10,353
18,823
11,455
5,972
2,419
1,921
2,053
6,452
5,158
6,258
6,667
5,367
4,673
4,371
5,025
3,622
4,961
3,351
4,399
8,310
6,598
7,900
5,380
3,190
3,437
5,480
4,987
3,549
2,240
6,136
8,752
7,974
6,113
7,469
4,970
3,254
18,983
17,461
12,638
9,983
8,625
10,066
7,685
4,048
6,496
3,689
3,689
3,232
3,727
3,691
3,691
4,320
5,541
4,220
4,220
8,392
8,529
7,396
7,396
3,351
2,634
3,820
3,544
2,137
2,406
2,4062,1373,5443,8202,6343,3517,3967,3968,5298,3924,2204,2205,5414,3203,6913,6913,7273,2323,6893,6896,4964,0487,68510,0668,6259,98312,63817,46118,9833,2544,9707,4696,1137,9748,7526,1362,2403,5494,9875,4803,4373,1905,3807,9006,5988,3104,3993,3514,9613,6225,0254,3714,6735,3676,6676,2585,1586,4522,0531,9212,4195,97211,45518,82310,35314,94812,85019,0502,5202,26907,4480003,287000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
2,000
2,008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001,50000000000000000000000000000000000000002,0082,00000000000000
       Net Receivables 
0
0
0
227
0
0
0
1,798
0
2,289
1,776
1,364
1,296
1,143
974
770
856
900
878
923
1,293
1,022
1,132
1,416
1,464
1,615
1,722
2,094
2,063
2,074
1,921
2,159
3,272
2,842
3,070
1,707
2,192
2,424
2,603
2,327
1,954
2,149
1,416
1,517
2,540
2,572
2,741
2,274
2,593
2,260
1,977
2,108
2,741
3,035
2,609
1,537
2,214
2,971
3,121
4,444
4,444
4,735
5,029
5,367
5,367
5,279
4,408
3,015
4,656
3,416
2,854
2,625
4,778
2,487
2,297
6,417
2,439
2,223
2,876
2,8762,2232,4396,4172,2972,4874,7782,6252,8543,4164,6563,0154,4085,2795,3675,3675,0294,7354,4444,4443,1212,9712,2141,5372,6093,0352,7412,1081,9772,2602,5932,2742,7412,5722,5401,5171,4162,1491,9542,3272,6032,4242,1921,7073,0702,8423,2722,1591,9212,0742,0632,0941,7221,6151,4641,4161,1321,0221,2939238789008567709741,1431,2961,3641,7762,28901,798000227000
       Other Current Assets 
0
0
0
144
0
0
0
360
0
187
78
3,172
3,145
861
602
1,098
1,029
619
444
758
667
611
396
811
630
603
395
611
507
339
273
66
380
419
331
150
566
549
483
647
421
358
190
592
506
461
672
1,505
942
793
2,101
853
1,554
1,578
1,737
1,547
1,494
1,696
1,526
1,917
299
2,025
2,048
2,438
428
2,770
3,087
0
663
3,519
3,226
0
1,593
3,315
3,230
703
4,621
4,395
4,009
4,0094,3954,6217033,2303,3151,59303,2263,51966303,0872,7704282,4382,0482,0252991,9171,5261,6961,4941,5471,7371,5781,5548532,1017939421,505672461506592190358421647483549566150331419380662733395076113956036308113966116677584446191,0291,0986028613,1453,172781870360000144000
   > Long-term Assets 
0
0
0
2,059
0
0
0
2,462
0
4,623
4,695
3,082
2,965
2,798
2,686
2,662
2,545
2,021
1,760
1,505
1,508
1,380
1,327
1,168
1,084
1,070
1,008
855
853
841
809
878
824
945
930
1,031
1,630
1,970
2,350
11,249
11,211
11,103
6,637
5,401
942
907
959
915
823
849
2,380
2,816
3,108
2,954
2,683
2,952
2,640
2,680
2,466
1,952
1,952
2,835
2,638
2,178
2,178
1,878
2,019
2,004
2,004
1,807
1,648
2,415
2,415
2,569
2,696
2,433
2,306
2,119
2,116
2,1162,1192,3062,4332,6962,5692,4152,4151,6481,8072,0042,0042,0191,8782,1782,1782,6382,8351,9521,9522,4662,6802,6402,9522,6832,9543,1082,8162,3808498239159599079425,4016,63711,10311,21111,2492,3501,9701,6301,0319309458248788098418538551,0081,0701,0841,1681,3271,3801,5081,5051,7602,0212,5452,6622,6862,7982,9653,0824,6954,62302,4620002,059000
       Property Plant Equipment 
0
0
0
1,959
0
0
0
1,940
0
2,224
2,160
2,207
2,235
2,227
2,221
2,303
2,243
1,839
1,674
1,432
1,350
1,273
1,218
1,108
1,016
1,019
957
802
784
722
685
806
753
730
729
800
908
987
1,046
971
946
867
807
795
863
835
892
850
764
794
798
1,239
1,496
1,358
1,200
1,136
988
935
817
727
727
1,704
1,540
365
1,328
1,004
1,075
1,129
1,129
1,037
922
879
879
835
785
906
839
783
738
7387838399067858358798799221,0371,1291,1291,0751,0041,3283651,5401,7047277278179359881,1361,2001,3581,4961,2397987947648508928358637958078679469711,0469879088007297307538066857227848029571,0191,0161,1081,2181,2731,3501,4321,6741,8392,2432,3032,2212,2272,2352,2072,1602,22401,9400001,959000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,150
10,150
10,150
5,500
4,538
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000004,5385,50010,15010,15010,150000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
522
0
2,399
2,535
875
730
571
465
359
302
182
86
73
158
107
109
60
68
51
51
53
69
119
124
72
71
215
201
231
722
983
1,304
10,278
10,265
10,236
5,830
4,606
79
72
67
65
59
55
1,582
1,577
1,612
1,596
1,483
1,816
1,652
1,745
1,649
1,225
1,204
1,131
1,098
850
848
874
944
875
869
770
726
1,536
1,554
1,734
1,911
1,527
1,467
0
0
001,4671,5271,9111,7341,5541,5367267708698759448748488501,0981,1311,2041,2251,6491,7451,6521,8161,4831,5961,6121,5771,5825559656772794,6065,83010,23610,26510,2781,304983722231201215717212411969535151686010910715873861823023594655717308752,5352,39905220000000
> Total Liabilities 
0
0
0
4,738
0
0
0
5,351
0
9,082
11,833
12,049
10,939
6,641
6,612
8,184
5,426
4,702
3,991
3,178
4,935
3,781
3,012
3,173
4,829
4,756
5,694
6,963
8,823
7,899
8,818
8,706
9,351
13,893
8,702
8,484
7,964
7,332
6,446
8,728
6,475
5,024
4,006
2,994
3,069
2,836
2,980
3,663
3,570
3,202
4,644
4,028
3,815
3,993
4,099
3,880
4,004
3,563
3,705
3,959
3,959
5,874
5,287
5,856
5,856
6,583
5,915
9,624
9,624
8,368
8,178
10,148
10,148
7,941
8,369
8,254
8,651
7,960
7,926
7,9267,9608,6518,2548,3697,94110,14810,1488,1788,3689,6249,6245,9156,5835,8565,8565,2875,8743,9593,9593,7053,5634,0043,8804,0993,9933,8154,0284,6443,2023,5703,6632,9802,8363,0692,9944,0065,0246,4758,7286,4467,3327,9648,4848,70213,8939,3518,7068,8187,8998,8236,9635,6944,7564,8293,1733,0123,7814,9353,1783,9914,7025,4268,1846,6126,64110,93912,04911,8339,08205,3510004,738000
   > Total Current Liabilities 
0
0
0
4,218
0
0
0
5,100
0
6,230
9,379
10,034
8,935
5,075
5,366
7,450
4,778
4,098
3,430
2,679
2,938
2,217
2,084
2,735
2,589
2,464
2,919
4,415
4,876
4,207
4,388
4,749
5,783
7,451
5,298
5,127
4,760
4,737
4,920
7,572
5,687
4,461
3,519
2,581
2,730
2,573
2,793
3,551
3,532
3,152
3,753
3,288
2,983
3,207
3,393
3,261
3,482
3,077
3,325
3,591
3,591
4,686
4,158
4,865
4,865
4,569
3,883
4,078
4,078
4,078
3,875
5,819
5,819
3,527
3,934
3,717
4,041
3,239
3,074
3,0743,2394,0413,7173,9343,5275,8195,8193,8754,0784,0784,0783,8834,5694,8654,8654,1584,6863,5913,5913,3253,0773,4823,2613,3933,2072,9833,2883,7533,1523,5323,5512,7932,5732,7302,5813,5194,4615,6877,5724,9204,7374,7605,1275,2987,4515,7834,7494,3884,2074,8764,4152,9192,4642,5892,7352,0842,2172,9382,6793,4304,0984,7787,4505,3665,0758,93510,0349,3796,23005,1000004,218000
       Short-term Debt 
0
0
0
977
0
0
0
519
0
1,776
5,646
6,062
5,912
1,675
1,730
2,013
1,607
1,140
665
261
179
100
64
204
207
147
674
907
804
852
944
1,415
1,481
1,477
1,134
1,259
657
573
37
143
63
8
6
87
35
1,016
872
114
66
28
12
197
226
191
158
377
345
231
190
322
463
468
291
481
732
237
200
0
836
1,062
848
0
1,058
511
276
687
534
388
225
2253885346872765111,05808481,06283602002377324812914684633221902313453771581912261971228661148721,01635876863143375736571,2591,1341,4771,4811,415944852804907674147207204641001792616651,1401,6072,0131,7301,6755,9126,0625,6461,7760519000977000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147
0
0
0
87
0
0
0
114
0
0
12
123
520
49
12
230
194
74
8
322
211
106
0
481
265
49
0
596
1,707
786
587
808
459
229
0
431
301
172
44
4417230143102294598085877861,70759604926548101062113228741942301249520123120011400087000147000000000000000000000000000000000000000
       Accounts payable 
0
0
0
906
0
0
0
2,774
0
2,286
2,003
2,551
1,814
1,430
1,515
2,977
1,792
1,288
1,633
1,565
1,319
1,129
885
981
826
976
786
669
782
605
879
816
692
783
504
808
1,025
1,027
1,638
735
943
1,051
942
932
1,202
1,161
1,464
1,337
1,368
1,284
1,092
1,255
774
1,275
1,400
1,272
1,336
1,362
1,101
2,756
1,255
2,292
2,159
3,860
2,086
3,202
2,430
1,769
1,769
1,876
1,583
1,641
1,641
1,074
1,302
841
1,090
987
864
8649871,0908411,3021,0741,6411,6411,5831,8761,7691,7692,4303,2022,0863,8602,1592,2921,2552,7561,1011,3621,3361,2721,4001,2757741,2551,0921,2841,3681,3371,4641,1611,2029329421,0519437351,6381,0271,0258085047836928168796057826697869768269818851,1291,3191,5651,6331,2881,7922,9771,5151,4301,8142,5512,0032,28602,774000906000
       Other Current Liabilities 
0
0
0
832
0
0
0
1,651
0
2,005
1,654
1,421
1,209
1,620
1,636
1,937
880
1,196
682
859
1,039
611
783
472
384
1,167
273
1,031
1,412
855
713
899
1,981
2,317
793
740
801
815
588
4,065
2,431
1,412
1,010
793
986
5
1
1,526
1,442
1,189
1,855
1,315
1,546
1,391
1,515
1,406
1,608
1,241
1,805
372
1,771
1,644
1,423
524
1,774
932
1,049
686
1,154
987
1,292
2,061
1,843
1,789
2,201
2,029
2,255
1,702
1,847
1,8471,7022,2552,0292,2011,7891,8432,0611,2929871,1546861,0499321,7745241,4231,6441,7713721,8051,2411,6081,4061,5151,3911,5461,3151,8551,1891,4421,526159867931,0101,4122,4314,0655888158017407932,3171,9818997138551,4121,0312731,1673844727836111,0398596821,1968801,9371,6361,6201,2091,4211,6542,00501,651000832000
   > Long-term Liabilities 
0
0
0
520
0
0
0
251
0
2,852
2,454
2,015
2,004
1,566
1,246
734
648
604
561
499
1,997
1,564
928
438
2,240
2,292
2,775
2,548
3,947
3,692
4,430
3,957
3,568
6,442
3,404
3,357
3,204
2,595
1,526
1,156
788
563
487
413
339
263
187
112
38
50
891
740
832
786
706
619
522
486
380
368
368
1,188
1,129
991
991
2,014
2,032
5,546
5,546
4,290
4,303
4,329
4,329
4,414
4,435
4,537
4,610
4,721
4,852
4,8524,7214,6104,5374,4354,4144,3294,3294,3034,2905,5465,5462,0322,0149919911,1291,18836836838048652261970678683274089150381121872633394134875637881,1561,5262,5953,2043,3573,4046,4423,5683,9574,4303,6923,9472,5482,7752,2922,2404389281,5641,9974995616046487341,2461,5662,0042,0152,4542,8520251000520000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,105
1,701
0
0
0
0
0
0
0
0
12
4
1
0
0
0
0
0
0
0
0
50
48
213
294
258
214
176
133
87
14
12
0
0
0
0
1,310
1,310
1,310
0
1,310
0
0
0
0
0
0
0
0
0
0
00000000001,31001,3101,3101,31000001214871331762142582942134850000000001412000000001,7012,1050000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
350
350
485
523
499
474
450
425
1,932
1,457
807
328
681
674
917
910
1,842
1,991
2,140
2,133
2,126
5,350
2,980
2,681
2,508
2,076
1,514
1,152
787
563
487
413
339
263
187
112
38
0
531
527
538
531
492
443
389
399
366
356
346
323
322
245
240
235
251
3,707
3,795
3,866
3,941
4,020
4,085
4,151
4,225
4,375
4,489
0
0
004,4894,3754,2254,1514,0854,0203,9413,8663,7953,7072512352402453223233463563663993894434925315385275310381121872633394134875637871,1521,5142,0762,5082,6812,9805,3502,1262,1332,1401,9911,8429109176746813288071,4571,932425450474499523485350350000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,842
1,991
0
0
0
0
0
0
0
0
1,514
1,152
787
563
487
413
339
263
187
112
38
112
843
527
538
531
492
443
389
399
366
356
346
323
322
245
240
0
0
0
229
0
0
0
0
0
0
0
0
0
0
0000000000229000240245322323346356366399389443492531538527843112381121872633394134875637871,1521,514000000001,9911,8420000000000000000000000000000
> Total Stockholder Equity
0
0
0
2,202
0
0
0
7,338
0
974
-2,033
14,901
9,598
13,399
8,281
15,428
10,739
5,075
1,846
2,269
941
6,189
5,564
7,045
5,545
4,547
2,719
1,701
387
-136
163
-868
342
-501
3,128
4,081
2,617
1,550
3,397
12,063
13,404
13,370
7,828
12,054
11,137
10,748
9,118
10,140
7,750
6,039
22,863
21,431
18,606
16,160
14,256
15,326
12,629
10,785
13,340
10,489
10,489
10,271
11,209
8,705
8,705
11,562
12,316
5,363
5,363
11,460
11,169
8,697
8,697
7,021
5,559
7,977
7,242
5,675
6,692
6,6925,6757,2427,9775,5597,0218,6978,69711,16911,4605,3635,36312,31611,5628,7058,70511,20910,27110,48910,48913,34010,78512,62915,32614,25616,16018,60621,43122,8636,0397,75010,1409,11810,74811,13712,0547,82813,37013,40412,0633,3971,5502,6174,0813,128-501342-868163-1363871,7012,7194,5475,5457,0455,5646,1899412,2691,8465,07510,73915,4288,28113,3999,59814,901-2,03397407,3380002,202000
   Common Stock
0
0
0
3,101
0
0
0
3,399
0
3,399
3,408
1
1
1
1
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
4
1
1
1
1
1
1
1
1
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
3
3
2
2
2
2
5
5
1
2
215522223322222222222111111111122222111111114333333333332222222211113,4083,39903,3990003,101000
   Retained Earnings Total Equity0000000000-179,2770-172,536-171,886-172,006-172,246-170,869-169,785-168,582-169,238-166,016-163,718-160,898-157,440-152,677-149,490-146,620-143,101-140,665-156,892-154,943-152,375-149,465-146,316-144,553-142,213-140,712-134,798-134,080-134,010-141,46700000000-127,999-127,1600000000000000000000000000000
   Accumulated Other Comprehensive Income -2,823-3,120-2,907-3,418-4,176-4,411-4,3120-4,571-4,506-4,5790-4,235-5,255-5,610-6,000-4,181-4,445-4,349-4,000-4,418-4,127-4,477-3,975-4,400-4,023-3,978-4,178-4,671-4,255-4,087-3,854-3,899-3,831-3,578-3,507-3,373-3,171-3,061-3,069-3,069-3,077-3,090-2,991-3,070-3,054-3,173-3,053-3,162-3,075-2,868-2,901-2,985-2,965-3,090-2,988-2,946-2,941-2,983-3,054-3,073-2,964-2,757-2,775-1,361-1,079-859-364-636-1400-795000-817000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,412
130,935
0
0
0
0
0
0
0
0
147,932
149,141
150,544
151,338
151,912
157,772
159,266
160,893
162,480
166,367
166,779
167,185
168,198
168,709
169,203
169,672
171,332
176,740
178,003
178,629
183,772
184,074
184,366
184,499
186,257
186,559
188,112
188,701
189,085
0
189,217
0
0
0
0
0
0
0
0
0
0
0000000000189,2170189,085188,701188,112186,559186,257184,499184,366184,074183,772178,629178,003176,740171,332169,672169,203168,709168,198167,185166,779166,367162,480160,893159,266157,772151,912151,338150,544149,141147,93200000000130,935130,4120000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
3,674
0
0
0
4,644
0
5,163
6,057
87,342
86,102
95,445
95,631
109,252
109,762
111,010
111,101
113,749
116,285
123,426
124,147
127,079
127,954
128,605
129,007
129,683
130,544
130,860
133,706
134,443
135,208
135,884
141,424
144,825
145,073
145,405
147,863
149,072
150,483
151,167
151,539
158,265
159,688
161,062
162,581
166,513
166,692
166,930
168,527
168,531
169,225
169,649
170,932
176,765
177,526
178,502
183,354
-4,349
183,725
184,054
186,076
-5,610
186,949
188,446
188,850
-4,579
189,217
196,438
197,156
-4,312
197,370
197,697
197,939
200,904
201,076
201,210
202,795
202,795201,210201,076200,904197,939197,697197,370-4,312197,156196,438189,217-4,579188,850188,446186,949-5,610186,076184,054183,725-4,349183,354178,502177,526176,765170,932169,649169,225168,531168,527166,930166,692166,513162,581161,062159,688158,265151,539151,167150,483149,072147,863145,405145,073144,825141,424135,884135,208134,443133,706130,860130,544129,683129,007128,605127,954127,079124,147123,426116,285113,749111,101111,010109,762109,25295,63195,44586,10287,3426,0575,16304,6440003,674000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue13,272
Cost of Revenue-8,795
Gross Profit4,4774,477
 
Operating Income (+$)
Gross Profit4,477
Operating Expense-9,047
Operating Income-4,570-4,570
 
Operating Expense (+$)
Research Development207
Selling General Administrative8,684
Selling And Marketing Expenses156
Operating Expense9,0479,047
 
Net Interest Income (+$)
Interest Income0
Interest Expense-16
Other Finance Cost-32
Net Interest Income16
 
Pretax Income (+$)
Operating Income-4,570
Net Interest Income16
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,184-3,956
EBIT - interestExpense = -4,586
-5,184
-5,135
Interest Expense16
Earnings Before Interest and Taxes (EBIT)-4,570-5,168
Earnings Before Interest and Taxes (EBITDA)-4,446
 
After tax Income (+$)
Income Before Tax-5,184
Tax Provision--33
Net Income From Continuing Ops-5,151-5,151
Net Income-5,151
Net Income Applicable To Common Shares-5,151
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses17,842
Total Other Income/Expenses Net-614-16
 

Technical Analysis of Sonoma Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sonoma Pharmaceuticals Inc. The general trend of Sonoma Pharmaceuticals Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sonoma Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sonoma Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.19 < 0.1919 < 0.2439.

The bearish price targets are: 0.1311 > 0.1301 > 0.1159.

Tweet this
Sonoma Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sonoma Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sonoma Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sonoma Pharmaceuticals Inc. The current macd is 0.00452147.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sonoma Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sonoma Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sonoma Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sonoma Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartSonoma Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sonoma Pharmaceuticals Inc. The current adx is 43.86.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sonoma Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Sonoma Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sonoma Pharmaceuticals Inc. The current sar is 0.1398612.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sonoma Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sonoma Pharmaceuticals Inc. The current rsi is 55.80. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Sonoma Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartSonoma Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sonoma Pharmaceuticals Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sonoma Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sonoma Pharmaceuticals Inc Daily Stochastic Oscillator ChartSonoma Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sonoma Pharmaceuticals Inc. The current cci is 88.87.

Sonoma Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartSonoma Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sonoma Pharmaceuticals Inc. The current cmo is 14.08.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sonoma Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartSonoma Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sonoma Pharmaceuticals Inc. The current willr is -44.15584416.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sonoma Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sonoma Pharmaceuticals Inc Daily Williams %R ChartSonoma Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sonoma Pharmaceuticals Inc. The current atr is 0.0191081.

Sonoma Pharmaceuticals Inc Daily Average True Range (ATR) ChartSonoma Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sonoma Pharmaceuticals Inc. The current obv is 334,101,387.

Sonoma Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartSonoma Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sonoma Pharmaceuticals Inc. The current mfi is 76.09.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Sonoma Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartSonoma Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sonoma Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Sonoma Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sonoma Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.800
Ma 20Greater thanMa 500.156
Ma 50Greater thanMa 1000.153
Ma 100Greater thanMa 2000.165
OpenGreater thanClose0.170
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sonoma Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Sonoma Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sonoma Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sonoma Pharmaceuticals Inc

I send you an email if I find something interesting about Sonoma Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Sonoma Pharmaceuticals Inc.

Receive notifications about Sonoma Pharmaceuticals Inc in your mailbox!